The findings provide real-world historical outcome data for patients who would now be considered candidates for adjuvant ribociclib and may serve as a benchmark for evaluating outcomes following adoption of adjuvant ribociclib.
H. Abdel-Razeq, M. Horani, F. Tamimi et al.· Drug Design, Development and...· 0 citations
A narrative review of phase II/III trials reporting radiographic progression-free survival (rPFS) or overall survival (OS) in mCRPC, including congress data, to June 2026, graded on a five-level evidence hierarchy to propose a hypothesis-generating four-track framework for discussion between clinicians and patients.
B. Sharaf, M. Al-Rwashdeh, O. El Khatib et al.· Cancers· 0 citations
In this real-world Middle Eastern cohort, pembrolizumab-based chemoimmunotherapy achieved pCR rates consistent with pivotal trial data, and Grade 3 histology, pathogenic germline mutation, and age younger than 40 years were independently associated with pCR.
B. Sharaf, T. Al-Batsh, Suhaib Khater et al.· Breast Cancer· 0 citations
Germline P/LP variants are common in young male patients with cancer, particularly at younger ages and among those meeting testing criteria, and these findings support broader implementation of germline testing to inform management and familial risk assessment.
H. Abdel-Razeq, Hira Bani Hani, Seif Alafeef et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
